Allon CEO adds voice to generic vs. brand-name drug war

In the News

Allon CEO adds voice to generic vs. brand-name drug war

Posted on June 8, 2012 by Allon Therapeutics
business-in-vancouver-logo

Allon’s President & CEO, Gordon McCauley, was quoted in the Business in Vancouver article, “Generic versus brand-name drug war heats up” on June 5, 2012. The article refers to the potential
conclusion of a deal between Ottawa and the European Union that includes extending drug patent protection.

McCauley and several prominent Canadian biotechnology Presidents & CEOs added their support to the agreement, claiming that B.C.’s biotechnology and pharmaceutical companies need similar patent protection to the EU to encourage innovation within the biotechnology sector.

Allon Therapeutics (TSX:NPC) is currently testing its lead product candidate, davunetide, in a pivotal
clinical trial in Progressive Supranuclear Palsy (PSP), a form of frontotemporal dementia. This pivotal trial is fully enrolled and is expected to complete patient dosing and release top-line data by late
2012.

The article can be found here: Generic Versus Brand-Name Drug War Heats Up

This entry was posted in In the News. Bookmark the permalink.